GlassScriptPhysician profile
Minh Q Thai
NPI 1609888411
$20,185.68
in general payments reported to CMS, 2019-2025
39 companies · $3,049 in 2025
The $3,049 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,991 · 2020: $2,271 · 2021: $3,347 · 2022: $3,454 · 2023: $2,929 · 2024: $3,145 · 2025: $3,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,122.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,774.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,765.38 | 2019-2025 | Linzess, Creon, Viberzi |
| Glaxosmithkline, LLC. | $1,664.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,375.61 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Janssen Pharmaceuticals, INC | $1,098.22 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $1,011.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Nestle Healthcare Nutrition INC. | $927.56 | 2020-2023 | |
| Gilead Sciences, INC. | $788.77 | 2021-2025 | Vemlidy |
| Aimmune Therapeutics, INC. | $786.26 | 2024-2025 | Zenpep |
| Amgen INC. | $761.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Ironwood Pharmaceuticals, INC | $506.68 | 2019-2025 | Linzess |
| Amarin Pharma, INC. | $488.09 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $435.93 | 2023-2025 | |
| Boston Scientific Corporation | $377.69 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Thai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.